| CPC C07D 471/04 (2013.01) [A61P 13/12 (2018.01); C07D 237/22 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 487/08 (2013.01); C07D 487/10 (2013.01)] | 10 Claims |
|
1. A compound represented by Formula (I) or (III), or a tautomer or a pharmaceutically acceptable salt thereof;
![]() wherein
R1 and R3 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, heteroaryl, halogen, —OH, —CN, -cycloalkyl, —O-alkyl, —O-cycloalkyl, —O-aryl, -aryl-O-aryl, —CF3, —C(H)F2, alkylene-CF3, alkylene-C(H)F2, —SO2-alkyl, and —O-alkylene-O-alkyl;
R2 is a -heterocyclyl-L-R4 selected from the group consisting of:
![]() wherein L is methylene or —C(R5)(R6)-, and R4 is aryl, alkylene-aryl, alkylene-heteroaryl, heteroaryl, or heterocyclyl;
![]() wherein R4 is an oxazole ring, pyrazole ring, pyridine ring, pyrazine ring, pyridazine ring, or pyrimidine ring, wherein R4 is substituted with at least one substituent independently selected from the group consisting of alkyl, cycloalkyl, halogen, —CN, —CF3, and -C(H)F2; and
(C) a -heterocyclyl-L-R4 wherein the heterocyclyl is selected from
![]() wherein R7 is H, alkyl, —O-aryl, —O-alkyl, or cycloalkyl; L is methylene or —C(R5)(R6)-; and R4 is aryl, alkylene-aryl, alkylene-heteroaryl, heteroaryl, or heterocyclyl;
R5 is independently H or alkyl; and
R6 is selected from the group consisting of alkyl and -CF3.
|